2014

iCo Therapeutics Elects Dr. Richard W. Barker and William Jarosz as Independent Directors

    VANCOUVER, June 5 /PRNewswire/ - iCo Therapeutics announced today the
 appointment of Dr. Richard W. Barker and William Jarosz to its board of
 directors.
     Dr. Barker is currently Director General of the Association of the
 British Pharmaceutical Industry (ABPI). His twenty years of experience
 includes a number of senior leadership roles in the UK and abroad and spans
 the pharmaceutical, biotechnology and medical informatics sectors.
     William Jarosz is currently a Partner in the global investment
 management firm Cartesian Capital Group, LLC. He has broad expertise in
 international private equity investments, cross-border acquisitions,
 capital markets, and corporate and securities laws.
     "We are thrilled to have both Dr. Barker and Mr. Jarosz join the
 iCoTherapeutics team," said company President and CEO Andrew Rae. "Their
 membership on our board adds strategic expertise in numerous capacities
 including both the clinical and business aspects of drug development."
     Prior to joining the ABPI, Dr. Barker was founder and president of New
 Medicine Partners, a consulting firm to pharmaceutical and biotech
 enterprises. His past roles include CEO of iKnowMed, a clinical decision
 support and pharmaceutical services business in oncology; Chief Executive
 of Chiron Diagnostics, General Manager of IBM's Worldwide Healthcare
 Solutions division, and leader of McKinsey's European healthcare practice.
     "iCoTherapeutics' strategic approach to drug development and
 commercialization is novel and sound," said Dr. Barker. "I look forward to
 working with the entire iCo team to provide a global perspective towards
 helping bring promising new opportunities to the treatment of eye
 diseases."
     Dr. Barker is currently a board member of the European Federation of
 Pharmaceutical Manufacturers and Associations (EFPIA) and council member of
 the international equivalent body (IFPMA). He serves on the board of
 Adlyfe, a company specializing in protein misfolding diseases. Dr. Barker
 holds a D. Phil in biophysics and a BA in chemistry both from Oxford
 University. His research is in biological magnetic resonance at Oxford,
 Leeds and Munich.
     Prior to helping found Cartesian Capital Group, LLC, Mr. Jarosz served
 as Managing Director and General Counsel of AIG Capital Partners, a
 subsidiary of American International Group, Inc., and as Managing Director
 of the AIG-Brunswick Millennium Fund. While at AIG Capital Partners, Mr.
 Jarosz was responsible for various private equity transactions for the
 firm's global private equity funds.
     Mr.Jarosz practiced law at Debevoise & Plimpton, specializing in
 international private equity investment and general corporate and
 securities transactions. He also served as a consultant to the World Bank
 on the regulation of Foreign Direct Investment in emerging markets. Mr.
 Jarosz is a graduate of the University of Montana, and received an MA in
 Law and Diplomacy from the Fletcher School at Tufts University and a JD
 from Harvard Law School.
     iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
 company focused on developing pre-existing drugs for a range of new
 conditions affecting isolated biological environments - areas such as the
 eye, spinal cord, or joints - where locally-administered application of
 these therapies would have minimal systemic distribution and fewer safety
 issues.
     For more information, visit the company website at:
 www.icotherapeutics.com
     Business Development Contact:              Finance/Investor Contact:
     Dr. John Clement, CTO                      Mr. John Meekison, CFO
     778.688.0644                               604.602.9414
 
     Media Contact:
     Amanda Smith, Principal, Smith Biotech
     604.626.6264
 
 

SOURCE iCo Therapeutics Inc.

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.